Prime Medicine
$3.71
191
+$0.46+14.15% 20:00 Today
-$0.03-0.72%23:32After hours
Statistics
Day High
3.71
Day Low
3.36
52W High
6.94
52W Low
2.67
Volume
143,547
Avg. Volume
-
Mkt Cap
672.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Sep 19
$0.80
Jun 19
$0.20
Dec 18
$0.21
Sep 18
$0.23
Jun 18
$0.15
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
30OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.41
-0.35
-0.3
-0.24
Expected EPS
-0.242061
Actual EPS
N/A
Financials
-4,342.44%Profit Margin
Unprofitable4.63MRevenue
-201.14MNet Income
Analyst Ratings
8.75Average Price Target
The highest estimate is 11.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PRME. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
Editas Medicine
EDIT
Mkt Cap477.63M
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Beam Therapeutics
BEAM
Mkt Cap3.07B
Pacific Biosciences of California
PACB
Mkt Cap419.62M
Twist Bioscience
TWST
Mkt Cap9.13B
Holdings
Regions
Sectors
About
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Show more...
CEO
Allan Reine
Employees
146
Country
United States
ISIN
US74168J1016
Listings
0 Comments
Share your thoughts
FAQ
What is Prime Medicine stock price today?▼
The current price of PRME is $3.71 USD — it has increased by +14.15% in the past 24 hours. Watch Prime Medicine stock price performance more closely on the chart.
What is Prime Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Prime Medicine stocks are traded under the ticker PRME.
Is Prime Medicine stock price growing?▼
PRME stock has risen by +21.64% compared to the previous week, the month change is a +25.76% rise, over the last year Prime Medicine has showed a +5.4% increase.
What is Prime Medicine market cap?▼
Today Prime Medicine has the market capitalization of 672.91M
When is the next Prime Medicine earnings date?▼
Prime Medicine is going to release the next earnings report on October 30, 2026.
What were Prime Medicine earnings last quarter?▼
PRME earnings for the last quarter are -0.24 USD per share, whereas the estimation was -0.26 USD resulting in a +6.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prime Medicine revenue for the last year?▼
Prime Medicine revenue for the last year amounts to 4.63M USD.
What is Prime Medicine net income for the last year?▼
PRME net income for the last year is -201.14M USD.
Does Prime Medicine pay dividends?▼
Yes, PRME dividends are paid quarterly. The last dividend per share was 0.8 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Prime Medicine have?▼
As of August 25, 2026, the company has 146 employees.
In which sector is Prime Medicine located?▼
Prime Medicine operates in the Health & Wellness sector.
When did Prime Medicine complete a stock split?▼
Prime Medicine has not had any recent stock splits.
Where is Prime Medicine headquartered?▼
Prime Medicine is headquartered in CAMBRIDGE, United States.